鏈接：https://www.abinscience.cn/product/71/959.html
名稱：Research Grade Urelumab烏瑞蘆單抗?
別名：Urelumab，烏瑞蘆單抗，抗體，BMS-663513
CAS: 934823-49-1???
貨號：HC336026
適用物種：Human
寄主物種：Homo sapiens
形式：Liquid
純度：>95%
克隆性：Monoclonal
同種型：IgG4-kappa
應(yīng)用：Research Grade Biosimilar
UniProt：Q07011
用途范圍：僅用于科研
靶點：Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA
儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
產(chǎn)品介紹：Urelumab 是一種人源的 IgG4 單克隆抗體，用作 CD137 激動劑，可增強 T 細胞和自然殺傷細胞的抗腫瘤活性，并增強 Rituximab 的細胞毒活性。Urelumab可用于彌漫性大 B 細胞淋巴瘤 (DLBCL)、濾泡性淋巴瘤 (FL) 和其他類型的非霍奇金淋巴瘤 (NHL) 的研究。abinScience產(chǎn)品具有親和力高，靈敏度高，特異性好，穩(wěn)定性強等優(yōu)勢。
產(chǎn)品購買聯(lián)系方式：027-87433958/17302791434
郵箱：info@abinscience.com
參考文獻：Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. PMID: 32052473
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. PMID: 36727218
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. PMID: 38458639
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. PMID: 29118009
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. PMID: 36576322
FcgammaR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab. PMID: 37575254
Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity. PMID: 36248847
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. PMID: 31143521
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. PMID: 35236742
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. PMID: 30410017
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. PMID: 27756788
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rgammanull Immunodeficient Mice. PMID: 26113085
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. PMID: 37339979
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. PMID: 34168049
4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T. PMID: 37433196
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. PMID: 34064598
Checkpoint Inhibition in Non-Hodgkin's Lymphoma. PMID: 29065421
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation. PMID: 38091375
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents. PMID: 37310433
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. PMID: 38309721
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function. PMID: 34580116
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. PMID: 27496866
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. PMID: 26137403
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. PMID: 23452415
A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. PMID: 36076251
4-1BB costimulation promotes bystander activation of human CD8 T cells. PMID: 33180337
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors. PMID: 38593226
Functional expression of CD137 (4-1BB) on T helper follicular cells. PMID: 26587331
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. PMID: 34172583
Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy. PMID: 38492435
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. PMID: 31105267
Costimulatory capacity of CD137 mAbs on T cells depends on elaborate CRD structures but not on blocking ligand-receptor binding. PMID: 37675596
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes. PMID: 29133290
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. PMID: 35110355
Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. PMID: 36176235
In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice. PMID: 35820360
4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. PMID: 28473315
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity. PMID: 31974274
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. PMID: 23460532
詳情請咨詢 abinScience 亞洲區(qū)官方子公司 —— 武漢艾必賽生物技術(shù)有限公司
官方網(wǎng)址：【中文】https://www.abinscience.cn
【英文】https://www.abinscience.com
武漢艾必賽生物技術(shù)有限公司成立于 2023 年，是 abinScience 在亞洲地區(qū)設(shè)立的官方全資子公司，全面負責(zé) abinScience 品牌在亞太市場的科研試劑推廣、銷售及技術(shù)支持工作。
依托嚴(yán)格的產(chǎn)品研發(fā)體系和國際化的質(zhì)量管理標(biāo)準(zhǔn)，武漢艾必賽與 AtaGenix、ProteoGenix 等知名品牌保持長期戰(zhàn)略合作，現(xiàn)已構(gòu)建起涵蓋抗體、重組蛋白、工具酶、試劑盒、實驗耗材在內(nèi)的多品類供應(yīng)體系，面向區(qū)域內(nèi)科研機構(gòu)、高校實驗室與生物醫(yī)藥企業(yè)，提供穩(wěn)定、高效、可信賴的產(chǎn)品與服務(wù)。
核心業(yè)務(wù)覆蓋：
? 抗體產(chǎn)品（單抗、多抗、重組抗體等）
? 蛋白與多肽試劑（標(biāo)簽蛋白、功能蛋白等）
? 分子與細胞實驗相關(guān)耗材
? 定制化研發(fā)服務(wù)（蛋白表達、抗體定制、親和力成熟等）
? 科研供應(yīng)鏈整合與項目配套支持
武漢艾必賽始終秉持“Empowering Bioscience Discovery”的理念，為亞太地區(qū)的生命科學(xué)研究持續(xù)注入高質(zhì)量動能。
